Th17/IL‐17A Drives Alveolar Bone Loss via the JAK/STAT3‐RANKL Axis in the Periodontal Ligament
IL-17A promoted RANKL expression through JAK/STAT3 activation in PDLCs. Tofacitinib, a clinically available JAK inhibitor, significantly attenuated alveolar bone loss in periodontitis.
Authors
- Weideng Wei (ORCID: https://orcid.org/0000-0003-0308-9277)
- Yuan Yue (ORCID: https://orcid.org/0000-0002-3076-4971)
- Xiaodong Feng (ORCID: https://orcid.org/0000-0002-5058-6527)
- Jiao Chen (ORCID: https://orcid.org/0000-0003-4903-1054)
- Ying Zhou (ORCID: https://orcid.org/0009-0004-8174-1106)
- Xiaoqiang Xia (ORCID: https://orcid.org/0009-0002-4245-5989)
- Jiuge Zhang
- Yixin Zhang (ORCID: https://orcid.org/0000-0002-6669-4995)
- Ping Zhang (ORCID: https://orcid.org/0000-0002-4585-9893)
- Lisheng Zhang (ORCID: https://orcid.org/0000-0002-9276-6454)
- Die Lv (ORCID: https://orcid.org/0000-0002-4482-8403)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- Zhejiang University Medical College Affiliated Stomatological Hospital (CN)
- Stomatology Hospital (CN)
Publication Details
- Journal
- Oral Diseases
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1111/odi.70154
- Citations
- 1
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China
- Sichuan University
- West China Hospital, Sichuan University